IGH (Immunoglobulin Heavy Locus)

These findings indicate that the Leader assay provides a more reliable assessment of SHM status, with higher concordance with SS. Although the FR1 assay may offer additional information regarding clonal patterns, its results should be interpreted cautiously. Given the limited sample size, further studies are warranted to validate these findings. Overall, the Leader assay appears to be more suitable as a primary tool for SHM evaluation, with FR1 results serving a complementary role when interpreted in clinical context.

P3, N=420, Not yet recruiting, AstraZeneca

Comorbidities, particularly vascular disease and diabetes mellitus , significantly affect survival outcomes in CLL patients. These findings highlight the importance of integrated management strategies that address both CLL and comorbid conditions, especially in populations with high cardiometabolic risk.

These updated APLC consensus recommendations provide clinicians across the APAC with an evidence-based, pragmatic framework for managing CLL. They aim to support treatment consistency, optimise sequencing strategies and address gaps in diagnostics, access and long-term survivorship care across diverse healthcare settings.

A subset of histiocytes showed weak BCL6 expression of uncertain significance. This case highlights the importance of recognizing cutaneous CSH, emphasizes evaluation for an underlying lymphoproliferative disorder, and illustrates immunohistochemical pitfalls that may complicate interpretation.

Comprehensive vitreous sampling incorporating perfusion fluid may improve cytologic detection in PVRL within a single-center setting. Routine MRI surveillance facilitates early detection of CNS relapse in patients with PVRL; however, a survival benefit cannot be established from this retrospective analysis.

Overall, duvelisib plus venetoclax was active in high-risk R/R CLL/SLL and RT, though serious adverse events occurred, including immune-mediated toxicities. NCT03534323.

Early-diagnosis CLL displays a biased IGHV repertoire with stereotyped configurations characteristic of CLL, including subsets that are rare in the normal B-cell repertoire. These findings support a central role for antigen-driven selection in shaping CLL evolution.

After receiving six cycles of brentuximab+doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy at our Department of Hematology (University of Debrecen), the patient achieved complete metabolic remission (CMR) and remains in good condition. HL-RT in CLL is relatively rare and generally associated with poorer outcomes, though it is typically more favorable than DLBCL-RT. In this case report, we highlight not only an uncommon anatomical location of HL-RT but also the absence of typical predisposing factors, such as a TP53 mutation, unmutated immunoglobulin heavy chain (IGHV) status, or a lack of 13q deletion.

Biologically, CD38-negative cnMCLs appear to be more likely driven by CD38-independent, alternative signaling pathways. From a clinical perspective, identification of CD38-negative cnMCLs by flow cytometry may help recognizing patients at increased risk for adverse genetic features, including TP53 inactivation.

P2, N=78, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting